Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

692
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
692
Amyloid Fibrils03:03

Amyloid Fibrils

9.9K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.9K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

270
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
270
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

738
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
738

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative anatomy and biophysical modeling of ascending neuromodulatory systems in the developing rat neocortex.

PLoS computational biology·2026
Same author

Layer-specific cellular composition of mouse primary somatosensory and human temporal cortex: a direct 3D confocal counting approach.

Frontiers in neuroanatomy·2026
Same author

Disentangling Multitrophic Interactions: How Vegetation Cover, Wild Boar, Deer, and Predators Shape Rodents Activity and Acorn Dispersal.

Integrative zoology·2026
Same author

MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders.

Cancer research·2026
Same author

ColoStem, a core oncofetal signature that identifies poor prognosis colorectal tumors.

British journal of cancer·2025
Same author

Immune, stress, and redox status biomarkers in newborn calves: Dynamics in serum and saliva during the first week of life.

Veterinary journal (London, England : 1997)·2025

Related Experiment Video

Updated: Sep 22, 2025

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
06:23

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

8.1K

Pyramidal cell axon initial segment in Alzheimer´s disease.

Alejandro Antón-Fernández1,2,3, Gonzalo León-Espinosa4,5, Javier DeFelipe1,2,6

  • 1Department of Functional and Systems Neurobiology, Instituto Cajal, CSIC, Madrid, Spain.

Scientific Reports
|May 24, 2022
PubMed
Summary

Hyperphosphorylated tau in Alzheimer's disease (AD) is linked to changes in the axon initial segment (AIS), a key neuronal region. These structural alterations in the AIS may impact neuronal function and contribute to AD pathology.

More Related Videos

An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices
07:57

An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices

Published on: April 11, 2018

7.0K
Technique for Intranasal Administration of α-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

584

Related Experiment Videos

Last Updated: Sep 22, 2025

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
06:23

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

8.1K
An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices
07:57

An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices

Published on: April 11, 2018

7.0K
Technique for Intranasal Administration of α-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

584

Area of Science:

  • Neuroscience
  • Cell Biology
  • Pathology

Background:

  • The axon initial segment (AIS) is crucial for neuronal action potential generation and activity regulation.
  • AIS structure is plastic and can change with neural activity or disease.
  • Hyperphosphorylated tau is a hallmark of Alzheimer's disease (AD).

Purpose of the Study:

  • To investigate the relationship between hyperphosphorylated tau and structural changes in the AIS in Alzheimer's disease.
  • To determine if AIS alterations occur in neurons with hyperphosphorylated tau.

Main Methods:

  • Immunocytochemistry using the AT8 antibody (phospho-tau S202/T205).
  • 3D confocal microscopy reconstruction.
  • Analysis of human brain tissue from Alzheimer's disease patients and non-demented controls.

Main Results:

  • Approximately half of cortical pyramidal neurons with hyperphosphorylated tau exhibited altered AIS length or position.
  • Common AIS changes included proximal shifts and lengthening.
  • Similar AIS alterations were observed in non-demented individuals with hyperphosphorylated tau.

Conclusions:

  • Accumulation of phospho-tau is associated with structural alterations of the AIS.
  • These AIS changes may impact normal neuronal activity.
  • AIS alterations could contribute to neuronal dysfunction in Alzheimer's disease.